Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Focus: Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors say
06:02am, Thursday, 21'st May 2026
Lower prices for weight-loss pills from Novo Nordisk and Eli Lilly are prompting patients to switch from compounded medications to branded Wegovy and Foundayo, according to Reuters interviews with nin
Best Weight Loss Drug Stocks to Buy in 2026
11:15pm, Wednesday, 20'th May 2026
Demand for weight-loss drugs has exploded, with material differentiation among the players in the niche. There's a clear leader, but that may not be the best investment option for you in 2026.
Novo Nordisk cautiously optimistic on key GLP-1 obesity study, says Deutsche Bank
10:46am, Wednesday, 20'th May 2026
Deutsche Bank has maintained its 'hold' rating on Novo Nordisk (NYSE:NVO) with a price target of DKK290 after hosting the Danish drugmaker's head of research and development, Martin Lange. Analyst Em
Novo Nordisk: 2 Reasons To Buy This GLP-1 Giant
05:49am, Wednesday, 20'th May 2026
I rated Novo Nordisk a Buy, trading at deep value after a 70% selloff and currently at ~10x trailing earnings. NVO's pipeline, including high-dose Wegovy, zenagamtide, and UBT251, positions it closer
Eli Lilly: Novo Nordisk Was Just A Warm-Up
10:00am, Tuesday, 19'th May 2026
Novo Nordisk (NOVO) is no longer viewed as a near-term threat, leaving Lilly's (LLY) Tirzepatide to dominate the injectable obesity and Type 2 Diabetes markets for ~1.5-2 years. I expect Foundayo to c
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party
08:45pm, Monday, 18'th May 2026
There is a need for more weight loss drug options, including oral pills. Viking Therapeutics is working on a promising one, though tolerability might be an issue.
Three Biotechs That Are Top Takeover Targets
01:55pm, Monday, 18'th May 2026
Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised full-
3 Deeply Undervalued Stocks You Can Buy for Less Than $100 Right Now
12:00pm, Monday, 18'th May 2026
Shares of Pfizer, Novo Nordisk, and PDD Holdings trade at incredibly low valuations right now. These stocks are trading at significant discounts relative to their future earnings.
Novo Nordisk A/S - share repurchase programme
09:38am, Monday, 18'th May 2026
Bagsværd, Denmark,18 May 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 1
Novo Nordisk's Wegovy pill maintains strong lead over Eli Lilly rival despite weekly dip, Citi says
09:05am, Monday, 18'th May 2026
Novo Nordisk's (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy continues to outpace its main competitor despite a slight weekly decline...
Novo Nordisk's Wegovy pill maintains strong lead over Eli Lilly rival despite weekly dip, Citi says
08:17am, Monday, 18'th May 2026
Novo Nordisk's (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy continues to outpace its main competitor despite a slight weekly decline in prescriptions, according to Citi's late
Novo Nordisk's next obesity battlefront: Winning beyond America
01:00am, Monday, 18'th May 2026
Novo Nordisk sees a "major opportunity" outside of the U.S. and says that telehealth partners could help grow the global market for weight loss drugs. The battle for dominance over the lucrative marke
As millions flock to GLP-1s, doctors warn of a rise in frailty caused by rapid muscle wasting
12:00pm, Sunday, 17'th May 2026
Losing muscle, as well as fat, is an unexpected downside of the popular drugs that isn't broadly discussed or immediately apparent.
Buy, Sell, or Hold Novo Nordisk at $46?
10:45am, Friday, 15'th May 2026
The bulk of Novo Nordisk's sales come from weight-loss and diabetes treatments. The biotech faces competition from companies like Eli Lilly and Pfizer, among others.
Hims & Hers Stock Drops After Earnings: Buying Opportunity or Warning Sign?
05:05am, Friday, 15'th May 2026
Hims and Hers continues growing rapidly, but shrinking margins and rising costs are beginning to test the company's long-term profitability story.
